Press Detail

PRESS RELEASE

Biotest increases EBIT significantly in the first quarter 2016

- Increased Guidance confirmed

- Good start of cooperation with Kedrion

- Dividend proposed

Dreieich, 12 May 2016. In the first quarter of 2016, the Biotest Group generated revenue of EUR 147.1 million, after EUR 142.5 million in the same period of the previous year. This corresponds to a percentage increase of 3.2 %. All segments contributed to this positive development.

In the regional analysis, Biotest generated sales growth in the regions Rest of Europe, Central and South America, Middle East and Africa, as well as Other Asia and Pacific. In the Other Asia and Pacific region, revenue doubled to EUR 15.8 million, i.e. 10.7 % of total sales were generated in this region.

EBIT at Group level increased in the first quarter of 2016 to EUR 8.6 million (same period in the previous year: EUR 0.1 million). The EBIT margin amounted to 5.8 % after 0.1 % in the previous year. While Biotest recorded an EBIT of EUR -6.4 million last year in the core segment Therapy, operating income was positive in the first three months of 2016 at EUR 0.5 million. EBIT in the Plasma & Services segment rose by 18.3 % to EUR 8.4 million.

The Biotest Group again recorded a positive operating cash flow of EUR 18.3 million in the first three months of 2016 (same period in the previous year: EUR 12.6 million).

Outlook:
The Board of Management continues to expect an increase in sales in the low single-digit percentage range for 2016 and an EBIT in the range of EUR 33 to 35 million.

The Quarterly statement is available on the company's website at http://www.biotest.de/ww/de/pub/investor_relations/publikationen/quartalsberichte.cfm

About Biotest

Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies. Biotest has more than 2,300 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: investor_relations@biotest.de

PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: pr@biotest.de

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover, Munich, Stuttgart

Disclaimer

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.